BioDelivery Sciences International is a pharmaceutical company with a focus on patients living with chronic pain and associated conditions. The company has built a portfolio of products that includes utilizing its proprietary BioErodible MucoAdhesive drug-delivery technology to develop and commercialize new applications of proven therapies aimed at addressing unmet medical needs. The company's product candidates include: BELBUCA for the management of pain severe enough to require long-term opioid treatment and for which alternative treatment options are inadequate; and Symproic for the management of opioid-induced constipation in adult patients with chronic non-cancer pain.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.